Boston, Massachusetts-based Vertex Pharmaceuticals Incorporated (VRTX) develops and commercializes therapies for treating cystic fibrosis (CF). Valued at $123.2 billion by market cap, the company invests in scientific innovation to create transformative medicines for people with serious diseases. The biotechnology company is expected to announce its fiscal second-quarter earnings for 2026 after the market closes on Monday, Aug. 3.
Ahead of the event, analysts expect VRTX to report a profit of $4.25 per share on a diluted basis, up 6.3% from $4 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.
